These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 20732645)

  • 1. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets.
    Gizinski AM; Fox DA; Sarkar S
    Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):463-77. PubMed ID: 20732645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
    Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
    Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantation and the CD28/CTLA4/B7 pathway.
    Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
    Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
    [No Abstract]   [Full Text] [Related]  

  • 4. CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation.
    Chai JG; Vendetti S; Amofah E; Dyson J; Lechler R
    J Immunol; 2000 Sep; 165(6):3037-42. PubMed ID: 10975813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTLA-4Ig: uses and future directions.
    Ben-Shoshan M
    Recent Pat Inflamm Allergy Drug Discov; 2009 Jun; 3(2):132-42. PubMed ID: 19519590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of B7-dependent responses in CD28-deficient mice.
    Green JM; Noel PJ; Sperling AI; Walunas TL; Gray GS; Bluestone JA; Thompson CB
    Immunity; 1994 Sep; 1(6):501-8. PubMed ID: 7534617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
    Fallarino F; Fields PE; Gajewski TF
    J Exp Med; 1998 Jul; 188(1):205-10. PubMed ID: 9653097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costimulatory regulation of T cell function.
    Chambers CA; Allison JP
    Curr Opin Cell Biol; 1999 Apr; 11(2):203-10. PubMed ID: 10209159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells.
    Liu PC; Ssu CT; Tsao YP; Liou TL; Tsai CY; Chou CT; Chen MH; Leu CM
    Arthritis Res Ther; 2020 Mar; 22(1):64. PubMed ID: 32228715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of CTLA-4 in the regulation and initiation of T-cell responses.
    Chambers CA; Krummel MF; Boitel B; Hurwitz A; Sullivan TJ; Fournier S; Cassell D; Brunner M; Allison JP
    Immunol Rev; 1996 Oct; 153():27-46. PubMed ID: 9010718
    [No Abstract]   [Full Text] [Related]  

  • 11. Co-stimulation in T cell responses.
    Chambers CA; Allison JP
    Curr Opin Immunol; 1997 Jun; 9(3):396-404. PubMed ID: 9203422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept mechanism of action: concordance with its clinical profile.
    Herrero-Beaumont G; Martínez Calatrava MJ; Castañeda S
    Reumatol Clin; 2012; 8(2):78-83. PubMed ID: 22104048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expanding world of co-stimulation: the two-signal model revisited.
    Chambers CA
    Trends Immunol; 2001 Apr; 22(4):217-23. PubMed ID: 11274928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the strength of co-stimulation through the B7/CD28 pathway alter functional T cell responses to altered peptide ligands.
    Murtaza A; Kuchroo VK; Freeman GJ
    Int Immunol; 1999 Mar; 11(3):407-16. PubMed ID: 10221652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD28/B7 costimulation: a review.
    Greenfield EA; Nguyen KA; Kuchroo VK
    Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction.
    Tatari-Calderone Z; Semnani RT; Nutman TB; Schlom J; Sabzevari H
    J Immunol; 2002 Dec; 169(11):6162-9. PubMed ID: 12444120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus (SLE) patients.
    García-Cózar FJ; Molina IJ; Cuadrado MJ; Marubayashi M; Peña J; Santamaría M
    Clin Exp Immunol; 1996 Apr; 104(1):72-9. PubMed ID: 8603537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.
    Egen JG; Allison JP
    Immunity; 2002 Jan; 16(1):23-35. PubMed ID: 11825563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen presentation by parenchymal cells: a route to peripheral tolerance?
    Marelli-Berg FM; Lechler RI
    Immunol Rev; 1999 Dec; 172():297-314. PubMed ID: 10631955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
    van Gool SW; Barcy S; Devos S; Vandenberghe P; Ceuppens JL; Thielemans K; de Boer M
    Res Immunol; 1995; 146(3):183-96. PubMed ID: 8525052
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.